Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive

Read the full 313 word article

User Sign In